alexa [Lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia].
Medicine

Medicine

General Medicine: Open Access

Author(s): Zhang X, Sun J

Abstract Share this page

Abstract OBJECTIVE: To explore the safety and efficacy of lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia (AIHA). METHODS: From May 2008 to February 2013, a total of 37 patients with newly diagnosed elderly AIHA patients were enrolled in the study, including 25 cases treated with prednisone 1 mg · kg⁻¹ · d⁻¹ for 4 weeks and 12 cases ineligible for glucocorticoid receiving rituximab (100 mg/week for 4 times). RESULTS: Of the 25 patients with conventional glucocorticoid, 5 cases (20.0\%) were complete remission (CR), 15 cases with partial remission (PR) and 5 cases without response. The overall response rate was 80.0\%. Of the 12 cases with rituximab, 8 cases (66.7\%) were CR, 3 cases with PR and 1 without response. The overall response rate was 91.7\%. A significantly higher CR rate was seen in lower dose of rituximab, as compared to that in conventional glucocorticoid (P=0.038). CONCLUSION: A lower dose of rituximab, with satisfactory safety and efficacy, was better than the conventional glucocorticoid in the treatment of elderly AIHA patients. This article was published in Zhonghua Xue Ye Xue Za Zhi and referenced in General Medicine: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords